FDPS (farnesyl diphosphate synthase) catalyses the formation of farnesyl diphosphate, a key intermediate in the synthesis of cholesterol and isoprenylated cellular metabolites. FDPS is also the molecular target of nitrogen-containing bisphosphonates, which are used as bone-antiresorptive drugs in various disorders. In the present study, we characterized the sterol-response element and NF-Y (nuclear factor Y)-binding site in the human FDPS promoter. Using a luciferase assay, electrophoretic mobility-shift assay and chromatin immunoprecipitation assay, we demonstrated that these elements are responsible for the transcription of the FDPS gene, and that its transcriptional activation is mediated by SREBP-2 (sterol-regulatory-element-binding protein 2) and NF-Y. We also investigated whether sterol-mediated FDPS expression is involved in the cell proliferation induced by zoledronic acid, an FDPS inhibitor. We show that the SREBP-2-and NF-Ymediated regulation of FDPS gene transcription modulates cell proliferation. These results suggest that SREBP-2 and NF-Y are required to trigger cell proliferation through the induction of FDPS expression and that the pharmacological action of zoledronic acid is involved in this pathway.
INTRODUCTION
FDPS (farnesyl diphosphate synthase) catalyses the formation of FPP (farnesyl diphosphate) by the head-to-tail condensation of dimethylallyl diphosphate with two molecules of isopentenyl diphosphate in the isoprenoid biosynthetic pathway [1] . FPP is a key intermediate and is utilized in the synthesis of sterols, dolichols, coenzyme Q, and the isoprenoid moiety of haem A [2, 3] . FPP is also necessary for the post-translational prenylation of small GTPases, which are involved in cell growth and survival, motility, cytoskeletal regulation, intracellular transport and secretion [4] [5] [6] [7] . Thus FDPS modulates many different cell functions through the synthesis of an isoprenoid.
FDPS is the molecular target of nitrogen-containing bisphosphonates, which are used as bone-antiresorptive drugs in disorders such as osteoporosis and Paget's disease [8] [9] [10] . Previous results suggest that inhibiting osteoclast activity with bisphosphonate may have an anticancer action via a pro-apoptotic and antiproliferative effects on tumour cells [11] [12] [13] [14] . These effects of bisphosphonates have been attributed to its inhibition of FDPS activity [15] . This inhibition leads to the induction of a caspase cascade, triggering apoptosis, because the lack of small GTPase prenylation causes poor cell functioning or programmed cell death [16] . These observations point to the clinical importance of FDPS.
Changes in FDPS activity are related to human disease. In the case of peroxisomal-deficiency diseases, FDPS activity is reduced in the liver tissue obtained from patients with diseases such as Zellweger syndrome and neonatal adrenoleucodystrophy [17] . Moreover, Levy et al. [18] suggest that a single-nucleotide polymorphism in the FDPS gene may be a genetic marker for low bone mineral density in post-menopausal Caucasian women. It is therefore necessary to determine the precise mechanism involved in the regulation of human FDPS expression.
SREBP (sterol-regulatory-element-binding protein) belongs to a large class of the basic helix-loop-helix leucine zipper family of transcription factors, and regulates the biosynthesis of both fatty acids and cholesterol [19] [20] [21] . Three SREBP isoforms (SREBP1a, -1c and -2) are known to exist in animal tissues, and the different proteins regulate target gene expression. SREBP-1c preferentially activates the lipogenesis genes, whereas SREBP-2 preferentially enhances the transcription of genes involved in cholesterogenesis. SREBP-1a regulates the synthesis of both cholesterol and fatty acids. All SREBPs are synthesized as transcriptionally inactive precursors on the endoplasmic reticulum as membrane proteins [19] . Once the intracellular cholesterol level is reduced, the SREBPs move in vesicles to the Golgi complex, where they are processed sequentially by two proteases. These cleavage steps release the mature forms of SREBPs, which enter the nucleus [21, 22] . Mature SREBPs can bind to SREs (sterolregulatory elements) in the promoters of target genes to regulate their transcription [23] . It is also well-known that either NF-Y (nuclear factor Y) or Sp1 (specificity protein 1) is necessary for sufficient transcriptional activation by SREBPs. Therefore most Abbreviations used: ChIP, chromatin immunoprecipitation; DMEM, Dulbecco's modified Eagle's medium; EMSA, electrophoretic mobility-shift assay; FBS, fetal bovine serum; FDPS, farnesyl diphosphate synthase; FPP, farnesyl diphosphate; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; LDLR, low-density lipoprotein receptor; LPDS, lipoprotein-deficient serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; NF-Y, nuclear factor Y; RT, reverse transcription; siRNA, small interfering RNA; SL2, Schneider line 2; Sp1, specificity protein 1; SRE, sterol-response element; SREBP, sterolregulatory-element-binding protein; WST-8, water-soluble tetrazolium salt 8. 1 To whom correspondence should be addressed (email doi@phs.osaka-u.ac.jp).
sterol-mediated promoters include either an NF-Y-binding site or an Sp1-binding site in addition to SREs. It has been demonstrated that the promoter of the rat Fdps gene contains three cis-acting elements [24] . These elements, an SRE and two NF-Y-binding sites, interact with SREBP-1a and NF-Y respectively. Although FDPS has recently attracted attention as a pharmacological target, the regulation of the human FDPS promoter is unknown. In the present study, we show that the human FDPS promoter is regulated by sterols via a mechanism involving SREBP-2 and NF-Y. The human FDPS promoter is shown to have a functional SRE and one NF-Y-binding site. We also examined the relationship between sterol-regulated FDPS and the effect of zoledronic acid on cell proliferation, a nitrogen-containing bisphosphonate. We show that FDPS expression induced by SREBP-2 and NF-Y modulates cell proliferation in human hepatoblastoma cells. These results suggest that SREBP-2 and NF-Y are required to trigger cell proliferation through the induction of FDPS expression and that the pharmacological action of zoledronic acid is involved in this pathway.
EXPERIMENTAL

Cell culture
Huh7 and HepG2 cells were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with heat-inactivated FBS (fetal bovine serum) (5 % for Huh7 cells and 10 % for HepG2 cells), 100 IU/ml penicillin and 100 μg/ml streptomycin. For the sterol-depletion experiments, the cells were cultured in DMEM supplemented with LPDS (lipoprotein-deficient serum). In some experiments, the cells were cultured in DMEM supplemented with either 10 μg/ml cholesterol plus 1 μg/ml 25-hydroxycholesterol or 50 μM pitavastatin [an HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitor] plus 50 μM sodium mevalonate. SL2 (Schneider line 2) cells, a continuous Drosophila cell line, were maintained in Schneider's medium containing 100 IU/ml penicillin and 100 μg/ml streptomycin supplemented with 10 % (v/v) FBS and were grown at 23
• C.
Plasmid constructs
The mature human SREBP-2 expression vector (pcDNA3-nSREBP2, amino acids 1-468) was obtained by subcloning pCMV-nSREBP-2 into the pcDNA3 vector (Invitrogen) [25] . The mature human SREBP-1a expression vector (pcDNA3-nSREBP1a, amino acids 1-460) was constructed as described previously [26] . The human FDPS expression vector (pcDNA3-hFDPS) was created by cloning the appropriate cDNA from HepG2-tet-off-hLXRα cells into the pcDNA3 vector [27] . The murine NF-YA29-expressing plasmid (pcDNA3-NF-YA29) has also been described previously [25] . pPac, a Drosophila actin 5C promoter-driven expression vector, pPac-β-gal, pPACnSREBP1a, pPacNF-YA, pPacNF-YB and pPacNF-YC have been described previously [25] . To generate human FDPS promoterreporter plasmids, the FDPS promoter containing nucleotides −1539 to +27 (FDPS-1539) was isolated by PCR from human genomic DNA extracted from HepG2 cells. The promoter was cloned into the PGV-B vector (Toyo Ink). A deletion construct was made and site-directed mutations were introduced into the FDPS promoter by PCR. The nucleotide sequences of these plasmids were confirmed by sequencing on an ABI PRISM ® 310 Genetic Analyzer (Applied Biosystems).
RNA extraction and real-time RT (reverse transcription)-PCR analysis
Total RNA extraction and cDNA synthesis were performed as described previously [26] . PCRs were performed with a QuantiTect ® SYBR Green PCR kit (Qiagen). Amplification specificity was verified by visualizing the PCR products on an ethidium-bromide-stained 2 % agarose gel. Cyclophilin A or 36B4 mRNA was used to normalize each expression datum. The primers used were: 5 -AAAGCAGGATTTCGTTCAGCA-3 and 5 -GGAATGCTACTACCACCGTCAA-3 for FDPS; 5 -GA-GTCCGGTACTGGAGCCAATC-3 and 5 -ATGGTCCCTCCA-AGTGAGATTC-3 for NF-YA; 5 -GCGTCTCCTTTGAGC-TGTTT-3 and 5 -TCACCACCCTGACACATAAACC-3 for cyclophilin A; and 5 -TGTTTCATTGTGGGAGCAGA-3 and 5 -TGAGGCAGCAGTTTCTCCAG-3 for 36B4.
Immunoblot analysis
To prepare whole-cell extracts, Huh7 cells were lysed in 25 mM Tris/HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 % NP-40 (Nonidet P40), 1 % sodium deoxycholate, 0.1 % SDS and protease inhibitor cocktail (Sigma). Each cell extract was resolved by SDS/PAGE (10% gels) and electroblotted on to nitrocellulose membrane. Western blot analysis was performed using anti-FDPS antibody (Abgent), anti-NF-YA antibody (Santa Cruz Biotechnology), anti-actin antibody (Santa Cruz Biotechnology) or anti-lamin B2 antibody (Abcam). The signals were visualized with the SuperSignal West Dura Extended Duration chemiluminescent substrate (Pierce).
Transfections and luciferase assay
DNA transfection of HepG2 cells was performed with Lipofectamine TM 2000 (Invitrogen), as described previously [26] . At 1 day before transfection, the cells were seeded at a density of 1.5 × 10 5 cells/well on 24-well plates. The cells were transfected with 200 ng of the FDPS reporter plasmid, 250 ng of pSV-β-galactosidase (Promega) and 100 ng of expression vector. At 4 h after transfection, the cells were cultured in DMEM supplemented with 10 % (v/v) FBS. After 20 h, assays for both luciferase and β-galactosidase activities were performed. The reporter activities were expressed as the relative luciferase activity/β-galactosidase activity.
DNA transfection of Huh7 cells was carried out with Lipofectamine TM 2000, as described by the manufacturer. The cells were seeded at a density of 1.2 × 10 5 cells/well on 24-well plates, and transfected with 300 ng of luciferase reporter plasmid, 400 ng of pSV-β-galactosidase and 100 ng of expression vector. The cells were harvested 24 h after transfection, and luciferase assays were performed as described above.
In the experiment using the dominant-negative NF-Y mutant (pcDNA3-NF-YA29), HepG2 cells were co-transfected with 200 ng of the FDPS reporter plasmid, 250 ng of pSV-β-galactosidase, 1 ng of pcDNA3-nSREBP1a, and 5, 25 or 100 ng of the NF-YA29 expression vector. The total amount of DNA was adjusted to 550 ng by the addition of the pcDNA3 vector.
DNA transfection of SL2 cells was carried out with Lipofectamine TM 2000, as described by the manufacturer. The cells were seeded at a density of 5 × 10 5 cells/well on 24-well plates, and transfected with 100 ng of luciferase reporter plasmid, 20 ng of pPac-β-galactosidase and the indicated amount of pPac-derived expression vector. The total amount of DNA was equilibrated by adding the appropriate amount of pPac vector. The cells were harvested 24 h after transfection, and luciferase assays were performed as described above.
EMSA (electrophoretic mobility-shift assay)
Nuclear extracts were prepared from Huh7 cells that had been cultured in DMEM supplemented with LPDS for 16 h. EMSAs were performed as described previously [27, 28] . In the competition studies, a 10-or 100-fold molar excess of unlabelled DNA was added to the reaction mixture. Supershift assays were performed using anti-(human SREBP-2) (Perseus Proteomics), anti-NF-YA antibody (Santa Cruz Biotechnology) or anti-PDI (control) antibody. Double-stranded DNAs of the following sequences were used for the binding and competition assays: wild-type human FDPS SRE, 5 -GCCATGCTCAC-ACGACGGCCAG-3 ; mutant FDPS SRE, 5 -GCCATGCTacaACGACGGCCAG-3 ; wild-type FDPS NF-Y-binding site, 5 -GCCAGCAGCCAATCAGCGCGGCT-3 ; and mutant FDPS NF-Y-binding site, 5 -GCCAGCAGCaccTCAGCGCGGCT-3 (mutated bases are shown in lower-case letters).
ChIP (chromatin immunoprecipitation) assay
ChIP assays were performed as described previously [27, 28] . Huh7 cells were cultured in DMEM supplemented with LPDS for 16 h. Antibody directed against SREBP-2 (Perseus Proteomics), NF-YA (Santa Cruz Biotechnology), mouse IgG (Santa Cruz Biotechnology) or rabbit IgG (Santa Cruz Biotechnology) was used. The precipitated DNAs were analysed by PCR using the primers 5 -CTAGACTTCAGCCCTTCCATTG-3 and 5 -GTTGGCGGGTACTCCTAAAAG-3 , which flank the SRE and NF-Y-binding site of the FDPS promoter.
Gene silencing experiments
Pre-designed siRNAs (small interfering RNAs) targeting SREBP-1, SREBP-2, NF-YA and FDPS mRNAs were provided by Qiagen. Huh7 cells were transfected with 25 nM siRNA using X-tremeGENE siRNA transfection reagent (Roche), as described by the manufacturer. As a control, we used the AllStars negative control siRNA (Qiagen), the sequence of which has no significant similarity to any mammalian gene. For the siRNA experiments, total RNA was extracted using the QuickGene RNA cultured cell HC kit S (Fujifilm).
Assays for cellular proliferation
We obtained zoledronic acid from Sequoia Research Products and dissolved it in PBS. The effects of zoledronic acid on Huh7 cells were measured by the WST-8 (water-soluble tetrazolium salt 8) method (Cell Counting Kit-8; Wako Chemical) based on the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay. Briefly, 4 × 10 3 cells/well on 96-well plates were incubated for 24 h in LPDS-or sterol-containing medium. At 24 h after seeding, 0.1, 1, 5, 10 or 50 μM zoledronic acid was added to the cells and they were incubated for 48 h. Then, 10 μl of Cell Counting Kit-8 solution was added, and the cells were incubated for another 1 h. The number of surviving cells was measured using a microplate reader (Bio-Rad Laboratories).
For the siRNA experiments, Huh7 cells were seeded at a density of 9 × 10 3 cells/well on 96-well plates and transfected with control, SREBP-1 or SREBP-2 siRNA for 24 h in DMEM supplemented with 5 % (v/v) LPDS. After 24 h, PBS or 50 μM zoledronic acid was added to the cells and they were incubated for 48 h.
In the experiment using the NF-YA siRNA, Huh7 cells were seeded at a density of 3 × 10 3 cells/well on 96-well plates and transfected with control or NF-YA siRNA for 48 h in DMEM supplemented with 5 % (v/v) FBS. After 48 h, PBS or 50 μM zoledronic acid was added to the cells and they were incubated for 48 h.
Statistical analysis
All data are presented as means + S.E.M. Statistical analyses were performed with the unpaired Student's t test or the DunnBonferroni test using Statcel version 2.0 (OMS Publishing).
RESULTS
Sterol depletion mediates FDPS expression in human hepatoblastoma cells
Previous studies have demonstrated that the FDPS gene is regulated by cellular sterols [1] . To confirm this regulation, we examined FDPS expression under various cellular sterol conditions. Human Huh7 hepatoblastoma cells were cultured for 24 h in one of three media supplemented as follows: with sterols (DMEM with LPDS, cholesterol and 25-hydroxycholesterol), LPDS (DMEM with LPDS) or statin (DMEM with LPDS, pitavastatin and sodium mevalonate). These three media contain sterols, LPDS or statin, and represent a decreasing order of intracellular sterols. We prepared total RNA from the cells and quantified the FDPS mRNA levels using real-time RT-PCR. As shown in Figure 1(A) , mRNA from the FDPS gene was significantly induced (3.0-fold) in LPDS-containing medium relative to that in sterol-containing medium. FDPS mRNA levels were also increased 3.8-fold when the cells were cultured in statin-containing medium. We examined further the sterol responsiveness of the FDPS gene at the protein level using Western blot analysis. Sterol depletion markedly increased FDPS protein levels, similar to the effect observed for mRNA ( Figure 1B) . These results indicate that the expression of FDPS is regulated by sterol depletion in human hepatoblastoma cells.
Transcriptional regulation of the human FDPS promoter by SREBPs and NF-Y
We next examined whether the expression of a human FDPS promoter-reporter gene was regulated in response to changes in cellular sterol conditions. We isolated the 5 -flanking region (−1539 to +27 bp) of the FDPS gene by PCR of human genomic DNA. The construct was transiently transfected into HepG2 cells and the cells were cultured with sterols, LPDS or statin for 20 h. Figure 2(A) shows that the activity of the FDPS-1539 promoter was dramatically increased in cells cultured with LPDS or statin compared with that in cells cultured with sterols. Thus the human FDPS promoter activity was regulated by cellular sterol levels.
Many studies have reported that the SREBP transcription factors control the gene expression associated with lipid metabolism in response to cellular sterol levels [19] . SREBP1a and SREBP-2, in particular, activate the cholesterogenesis genes. To determine whether this phenomenon is attributable to the effects of SREBPs, HepG2 cells were co-transfected with FDPS-1539 and the expression construct encoding the active form of SREBP-1a (amino acids 1-460) or SREBP-2 (amino acids 1-468). As under sterol-depleted conditions, the luciferase activity expressed from the FDPS-1539 promoterreporter construct significantly increased in the presence of SREBP-1a or SREBP-2 compared with the luciferase activity in the presence of the empty vector ( Figure 2B ). We then constructed various deleted versions of the promoter-reporter construct and performed luciferase assays ( Figure 2B ). Similar regulatory responses were observed for the FDPS-1079, FDPS-577, FDPS-292 and FDPS-264 constructs, whereas there was no increase with the FDPS-151 construct. These results strongly suggest that the region between nucleotides −264 and −151 contains the cisacting element necessary for the SREBP-mediated transcriptional regulation of FDPS.
Alignment of the proximal promoters of the human, mouse and rat FDPS genes revealed that the conserved sequence within the region between nucleotides −264 and −151 is an SRE motif (from −234 to −225; Figure 3) . Previous work has shown that the SRE motif in the rat Fdps promoter is located in close proximity to the two NF-Y-binding sites, which are apparently essential for the optimal regulation of sterol-sensitive genes [24] . When we searched for the NF-Y-binding sites around the SRE motif of the human FDPS promoter, only one NF-Y-binding site was located between nucleotides −215 and −211, which is a highly conserved region in the three species. Interestingly, this differs from the rat (and mouse) promoter, which has two NF-Y-binding sites. The conservation of these elements suggests that this is likely to be an important regulatory sequence.
To test the hypothesis that the SRE motif and the NF-Ybinding site are responsible for the regulation of FDPS by cellular sterols, we introduced a mutated version of these elements into the human FDPS promoter and performed luciferase assays in HepG2 Figure 4A ). The mutated constructs of either the SRE (SREmut) or NF-Y-binding site (NF-Ymut) resulted in approx. 30 % of the wild-type (FDPS-1539) luciferase activity when HepG2 cells were co-transfected with an nSREBP-1a expression plasmid ( Figure 4B ). A construct with mutations at both the SRE and NF-Y-binding site (SRE/NF-Ymut) showed markedly reduced luciferase activity. We also performed luciferase assays with all of the mutated constructs in the context of nSREBP-2 overexpression ( Figure 4B ). The luciferase activity showed a similar tendency to the results seen for nSREBP-1a, although the reduction in luciferase activity was weak compared with that for nSREBP-1a. We also performed the luciferase assay with all the mutated constructs in Huh7 cells, and the results were consistent with the results for HepG2 cells described above ( Figure 4C ).
cells (
To investigate further the requirement for NF-Y binding to the FDPS promoter, a dominant-negative NF-YA mutant expression vector, NF-YA29, was co-transfected with the FDPS-1539 promoter construct and nSREBP-1a into HepG2 cells.
NF-Y is a heteromeric transcription factor consisting of at least three subunits (NF-YA, NF-YB and NF-YC) [29, 30] . NF-YB and NF-YC form a tight complex, and this complexation is a prerequisite for NF-YA binding to form NF-Y. NF-YA29, in which three amino acids in the DNA-binding domain of NF-YA have been mutated, forms a complex with NF-YB and NF-YC, rendering it functionally inactive as a transcription factor. As shown in Figure 4(D) , the luciferase activity in the FDPS promoter was reduced in a dose-dependent manner. These results demonstrate that both the SRE and the NF-Y-binding site are important in the regulation of FDPS transcription.
Having demonstrated that SREBP and NF-Y are required for the sterol responsiveness of FDPS expression, we examined the ability of NF-Y to directly activate the FDPS gene together with SREBP. For this purpose, we took advantage of a modified co-transfection assay system in Drosophila SL2 cells. The cell line does not express functional equivalents of several mammalian transcriptional regulatory proteins, including the active endogenous SREBPs and NF-Y [31] . Therefore it is an ideal cell-based assay system for the analysis of transcription factor requirements for promoter activation because it provides a negative background [32] . 
SREBP-2 and NF-YA gene knockdown affects FDPS expression
We next examined whether the expression of FDPS was reduced when Huh7 cells were transfected with SREBP-specific siRNA. We have already evaluated the SREBP siRNAs in a previous study, and these siRNAs function effectively and in a subtype-specific manner [26] . Quantitative RT-PCR demonstrated that FDPS mRNA levels were reduced by 40 % after cell transfection with SREBP-2 siRNA, whereas FDSP mRNA did not change in cells transfected with SREBP-1 siRNA ( Figure 5A ). We also examined FDPS protein in a Western blotting experiment. Consistent with the results for mRNA, the level of FDPS protein was reduced in SREBP-2-knockdown cells compared with that in the control cells ( Figure 5B ). These results indicate that endogenous FDPS expression is regulated by SREBP-2 in Huh7 cells.
We also suppressed the expression of the endogenous NF-YA gene in Huh7 cells using a NF-YA-specific siRNA and examined the expression of FDPS. The mRNAs encoding NF-YA were reduced by approx. 60 % in cells transfected with NF-YA siRNA compared with those of the control cells (see Supplementary Figure 1A at http://www.BiochemJ.org/bj/429/bj4290347add.htm). Consistent with the reduction in NF-YA mRNA, the levels of NF-YA protein were reduced in cells transfected with siRNA for NF-YA compared with those of the control cells (Supplementary Figure 1B) . We then examined FDPS mRNA levels to analyse whether the knockdown of NF-YA gene reduces FDPS expression. Quantitative RT-PCR demonstrated that FDPS mRNA levels were reduced by approx. 30 % after cell transfection with NF-YA siRNA ( Figure 5C ). The expression of FDPS protein was reduced by transfection of NF-YA siRNA into Huh7 cells compared with control cells (Figure 5D ).
SREBP-2 and NF-YA bind directly to each cis-acting element in the FDPS promoter
SREBP-2 affinity for the FDPS SRE sequence was evaluated by EMSA using nuclear extracts prepared from LPDS-treated Huh7 cells ( Figure 6A ). When the FDPS SRE was used alone, a protein-DNA complex was detected (lane 2). This complex appeared to be specific because the addition of excess unlabelled FDPS SRE probe (FDPS) prevented its formation (lanes 3 and 4) , whereas an unlabelled mutated SRE probe (FDPSmut) did not (lanes 5 and 6). The consensus SRE sequence identified in the promoter of the LDLR (low-density lipoprotein receptor) gene (positive control) was used as the control. The addition of excess unlabelled LDLR SRE specifically competed with the protein-DNA complex (lanes 7 and 8). Supershift analysis was then performed to identify the protein bound to the SRE. The protein-DNA complex band was supershifted by the addition of anti-SREBP-2 antibody (lane 9). Conversely, a control antibody had no significant effect (lane 10). These results demonstrate that SREBP-2 binds to the FDPS SRE at nucleotides −234 to −225.
To investigate the DNA-binding activity of NF-Y at the NF-Ybinding site of the FDPS promoter, an EMSA was performed using this response element ( Figure 6B) . A specific protein-DNA complex was detected (lane 12). Excess unlabelled NF-Y DNA probe or the consensus NF-Y sequence competed with the protein-DNA complex formation, whereas a mutated version of the NF-Y-binding site failed to compete for NF-Y binding (lanes [13] [14] [15] [16] [17] [18] . The complex was supershifted by the addition of anti-NF-YA antibody, confirming that NF-YA binds to the NF-Y-binding site of FDPS (lanes 19 and 20) . These results demonstrate that NF-Y binds to the NF-Y-binding site at nucleotides −215 to −211 of the FDPS promoter.
To determine whether SREBP-2 and NF-Y bind to the FDPS promoter in Huh7 cells, we performed a ChIP assay (Figure 7) . The binding of both SREBP and NF-Y to their sites on the FDPS promoter was confirmed by the ChIP assay using specific antibodies against each of these transcription factors. The precipitated cis elements (SRE and the NF-Y-binding site) were detected by PCR amplification of the FDPS promoter fragment (nucleotides −287 to −30), which included the SRE (nucleotides −234 to −225) and the NF-Y-binding site (nucleotides −215 to −211). As shown in Figure 7 , SREBP-2 bound to the human FDPS promoter in cells, whereas a negative mouse IgG showed very low non-specific background binding (lanes 2 and 3) . Similarly, antibody directed against NF-YA detected that protein bound to the NF-Y-binding site on the FDPS promoter (lane 6). These results indicate that SREBP-2 and NF-YA bind to the cisacting elements in the FDPS promoter in Huh7 cells.
FDPS induced by SREBP-2 and NF-Y regulates cell proliferation in hepatoblastoma cells
Zoledronic acid, which is one of the bisphosphonates, suppresses cell proliferation by inhibiting FDPS activity [33] . Zoledronic acid is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer [34] . It can also be used to treat the hypercalcaemia of malignancy and can be helpful for treating pain from bone metastases. However, how sterol-mediated FDPS is affected by zoledronic acid in the liver is largely unknown. To address this question, we investigated how cell proliferation is affected by sterol depletion and zoledronic acid.
We first examined whether cell proliferation changed with different cellular sterol contents. Figure 1(B) showed that the expression of FDPS protein in LPDS-containing medium is similar to that in statin-containing medium. Thus we adopted LPDS-containing medium as a sterol-depleted condition. We ChIP assays were performed using LPDS-treated Huh7 cells. Soluble chromatin was immunoprecipitated with pre-immune mouse IgG, rabbit IgG, anti-SREBP-2 antibody or anti-NF-YA antibody. Immunoprecipitates were subjected to PCR with a primer pair specific for the FDPS promoter. As a negative control, a second set of primers was used to amplify another genomic region that was not expected to interact with SREBP-2 or NF-YA. PCR was performed on the total chromatin input.
examined cell proliferation in LPDS-or sterol-containing medium by the WST-8 method, based on the MTT assay. As shown in Figure 8 (A), cell proliferation of Huh7 cells was reduced to 65 % in sterol-containing medium relative to that in LPDScontaining medium. These results suggest that cell proliferation is regulated in a sterol-dependent manner. To provide more direct evidence that FDPS affects cell proliferation, we examined cell viability in hepatoblastoma cells with elevated level of FDPS by transfection of FDPS cDNA. Figure 8 Figure 8C ). These results suggest that the FDPS induced by sterol depletion modulates cell proliferation.
Next, Huh7 cells were treated with various concentrations of zoledronic acid (0.1, 1, 5, 10 and 50 μM) in LPDS-or sterol-containing medium, and the effects of zoledronic acid on cells were measured by the WST-8 method ( Figure 8D ). In LPDS-containing medium, the exposure of Huh7 cells to increasing concentrations of zoledronic acid caused a dosedependent reduction in cell proliferation. This reduction in cell proliferation was almost identical with that in the sterol-treated cells described above. When cells were cultured with sterols, the reduction induced by zoledronic acid did not occur. These results suggest that the inhibition of cell proliferation by zoledronic acid occurs under sterol-depleted conditions when FDPS expression increases.
Finally, we determined the effects of zoledronic acid on the proliferation of Huh7 cells transfected with control, SREBP-1 or SREBP2 siRNA. We found that zoledronic acid treatment significantly reduced the proliferation of cells transfected with either the control or SREBP-1 siRNA ( Figure 8E ). However, when the cells were transfected with SREBP2 siRNA, treatment with zoledronic acid affected cell proliferation negligibly. In addition, we investigated the effects of zoledronic acid on the proliferation of Huh7 cells transfected with NF-YA siRNA. Consistent with the SREBP-2 siRNA, treatment with zoledronic acid did not affect cell proliferation when the cells were transfected with NF-YA siRNA ( Figure 8F ). These results show that FDPS induced by SREBP-2 and NF-Y regulates cell proliferation in hepatoblastoma cells.
DISCUSSION
The FDPS gene encodes an enzyme that catalyses the production of geranyl pyrophosphate and farnesyl pyrophosphate from isopentenyl pyrophosphate and dimethylallyl pyrophosphate [1] . The resulting product, FPP, is a key intermediate in cholesterol and sterol biosynthesis, a substrate for protein farnesylation and geranylgeranylation, and a ligand or agonist for certain hormone receptors and growth factor receptors [2] [3] [4] [5] [6] [7] . The present study confirms that the human FDPS promoter is a target of SREBP-2 and provides several novel insights into the cellular response to sterol depletion in terms of the expression of FDPS. We have shown that sterol depletion induces the mRNA and protein expression of the FDPS gene in human hepatoblastoma cells (Figure 1) . The transient overexpression of SREBP-1a or SREBP-2 activates the human FDPS promoter (Figures 2 and 4) . Conversely, the suppression of SREBP-1 or SREBP-2 by siRNA indicated that endogenous SREBP-2, but not SREBP-1, regulates the FDPS gene ( Figure 5) . Interestingly, previous studies have reported that the SRE of the rat Fdps promoter is regulated by SREBP-1a overexpression [24] . SREBP-1a is a potent activator of all SREBP-responsive genes, including those that mediate the synthesis of cholesterol, fatty acids and triacylglycerols [35] . However, SREBP-1a is expressed only at low levels in the livers of adult mice, rats, hamsters and humans. Studies of Srebp-1a transgenic mice have demonstrated that SREBP-1a has a relative preference for activating fatty acid synthesis rather than cholesterol synthesis. SREBP-2 preferentially enhances the transcription of genes involved in cholesterogenesis. These observations support the proposition that FDPS, a key enzyme in the cholesterol synthesis pathway, is mainly controlled by endogenous SREBP-2.
The ubiquitous transcription factor NF-Y is also an important regulator of FDPS gene expression, and the transcription of the FDPS gene is regulated by a combination of SREBPs and NF-Y (Figures 4 and 5) . NF-Y binds to NF-Y-binding sites in the promoter regions of a variety of genes involved in early mouse development and cell-cycle progression [30, 36] . The NF-Y complex comprises three subunits, NF-YA, NF-YB and NF-YC, all required for DNA binding. The SREBP-mediated induction of target gene expression occurs in concert with the additional binding of co-regulatory NF-Y to the promoter, resulting in synergistic levels of transcriptional activation [23] . Several genes, including those encoding squalene synthase, HMG-CoA synthase and lipin 1, are regulated by the same combination of transcription factors [26, 37, 38] . NF-Y-binding sites are usually found in close proximity to SREs in the promoters of these genes. In the human FDPS gene, the distance between the SRE and the NF-Y-binding site is approx. 9-bp, and these two cis-acting elements are the regions essential for the transactivation of the FDPS promoter by SREBPs and NF-Y. Interestingly, the rat Fdps gene has another NF-Y-binding site upstream of the SRE [24] . The distances between the two binding sites for SREBP and NF-Y in the promoter of rat Fdps are in the 21-bp range and this spacing is highly conserved in the mouse Fdps gene (Figure 3) . It is likely that the regulation of the human FDPS gene differs from that of the rodent genes. Recently, Romanelli et al. [39] showed that the FDPS gene expression of humans and chimpanzees, but not of rodents, involves the transcription factors Pax5 and OCT-1 [39] . Martín et al. [40] showed that human FDPS has a novel alternatively spliced isoform, which is expressed in the mitochondria. These observations suggest the different regulation of human and rodent FDPS genes.
It is clear from these results that the effect of zoledronic acid on cell proliferation is critical for the effect of SREBP-2 ( Figure 8 ). Studies in Dictyostelium discoideum have reported that the overexpression of FDPS leads to resistance to the growthinhibitory effects of nitrogen-containing bisphosphonates [41, 42] . Recent studies have also demonstrated that HMG-CoA reductase inhibitors (statins), cholesterol-lowering agents, suppress cell proliferation in various types of tumour cells [43] . HMG-CoA reductase is the rate-limiting enzyme in the cholesterol synthesis pathway, and the growth-inhibitory effect of statins acts with the same mechanism as zoledronic acid. These observations support our results demonstrating that FDPS induced by SREBP-2 regulates cell proliferation. The anti-proliferative effect of zoledronic acid works effectively when SREBP-2 is activated. Interestingly, it has been reported that FDPS is highly expressed in tumour cells. Notarnicola et al. [11] showed that FDPS expression levels are significantly higher in cancer samples than in normal mucosa. Elevated FDPS expression has also been observed in rat prostate tumour cell lines [44] . FDPS probably plays a significant role in various types of tumour cells. Therefore the potential therapeutic applicability of zoledronic acid in various types of tumour cells appears to be relevant and it could be used not only in tumour-associated bone disease therapies, but also in the treatment of liver cancer.
In conclusion, we have demonstrated that intracellular sterols modulate the expression of the human FDPS gene via SREBP-2 and NF-Y. We have also clarified that the expression of FDPS induced by SREBP-2 and NF-Y controls cell proliferation. This regulation of the human FDPS gene may play a role in tumour therapies through the anti-proliferative effects of zoledronic acid.
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